Rui Tato Marinho ruitatomarinho@sapo.pt
Department of Gastroenterology and Hepatology
Current and Future Liver Treatment Options
Current and Future Liver Treatment Options Rui Tato Marinho - - PowerPoint PPT Presentation
Current and Future Liver Treatment Options Rui Tato Marinho ruitatomarinho@sapo.pt Department of Gastroenterology and Hepatology President of College of Hepatology of Portuguese Medical Association (2012-2015) Editor-Chief of Acta Mdica
Rui Tato Marinho ruitatomarinho@sapo.pt
Department of Gastroenterology and Hepatology
Current and Future Liver Treatment Options
President of College of Hepatology of Portuguese Medical Association (2012-2015) Editor-Chief of Acta Médica Portuguesa (2011-2016) Vice-President of Portuguese Society of Gastroenterology (2013-2017) President of Scientific Committee of SOS Hepatitis, patient NGO Member of Scientif Committee of Port. Ass. Haemophilia Infarmed – Coordinator of Consultive Panel for Hepatitis C (2014-2015) Direção-Geral da Saúde – National Strategy for Viral Hepatitis ACSS – referentiation group for digestive diseases Pedagogic Committee of Medical School of Lisbon (2014-2017) Scientific Committee of Masters in Palliative Care Elected Member of General Assembly of United European Gastroenterology, Advisory Member of Viral Hepatitis Prevention Board (WHO, CDC, ELPA, ECDC) Fellowship of EBGH, American College of Gastroenterology, Sociedade Brasileira de Hepatologia Conflict of Interests: Abbvie, BMS, MSD, Gilead, Janssen
“Core Business” 32% with cirrhosis ~52-63% with F3/F4 A person with 52 years
Data from National Registry for HCV treatment, Infarmed Portugal, 2016
Sustained Viral Response (SVR) = virological cure
HCV RNA negative 3 months after the end of therapy for ever and ever (>99%)
Cure hepatitis C (genotype 1)
Adapted from Hepatitis C, stigma and cure. Marinho RT, Barreira D, World Journal Gastroenterology 2013
1986 1995 2000 2011 2013/2014
IFN SC 3Xw 24w IFN SC 3Xw + RBV 48w PEG-IFN SC 1Xw + RBV 48w PEG-IFN 1Xw + RBV 24-48w + Boceprevir / Telaprevir Oral DAAs 12w
Sustained Viral Response Non Response
N 130
2011
No Response SVR -Response
Daclatasvir Paritaprevir, Ombitasvir, Dasabuvir Simeprevir Sofosbuvir Sofosbuvir/Ledipasvir
DAA – Direct-Acting Antiviral
SVR 96% SOF/LDV
EMA 26th May 2016
Velpatasvir/Sofosbuvir Grazoprevir/Elbasvir
pharmaceutical industry, patients, journalists, etc)
Saving lives and Families
pharmaceutical industry, patients, journalists, etc)
Acute Hepatitis
Chronic Hepatitis Compensated Cirrhosis Decompensated Cirrhosis
HCC
Transplant
Palliative Care
Death